

PCSK9 genetic variants and risk of type 2 diabetes: a me

Lancet Diabetes and Endocrinology, the
5, 97-105

DOI: [10.1016/s2213-8587\(16\)30396-5](https://doi.org/10.1016/s2213-8587(16)30396-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Common and rare genetic variants and risk of CHD. <i>Nature Reviews Cardiology</i> , 2017, 14, 73-74.	6.1	8
2	Bococizumab for the treatment of hypercholesterolaemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 237-243.	1.4	20
3	PCSK9 inhibition and the global diabetes epidemic. <i>Diabetologia</i> , 2017, 60, 751-752.	2.9	0
4	Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish. <i>Diabetes</i> , 2017, 66, 2054-2058.	0.3	28
5	Alirocumab for the treatment of hypercholesterolaemia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 571-582.	1.3	9
6	Dyslipidaemia in type 2 diabetes mellitus. <i>Current Opinion in Cardiology</i> , 2017, 32, 422-429.	0.8	26
7	Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease. <i>Basic Research in Cardiology</i> , 2017, 112, 32.	2.5	66
8	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. <i>Metabolism: Clinical and Experimental</i> , 2017, 74, 43-46.	1.5	19
9	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2017, 4, CD011748.	1.5	93
10	Human genetics as a model for target validation: finding new therapies for diabetes. <i>Diabetologia</i> , 2017, 60, 960-970.	2.9	19
11	The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 754-762.	0.4	6
12	Leveraging Human Genetics to Understand the Relation of LDL Cholesterol with Type 2 Diabetes. <i>Clinical Chemistry</i> , 2017, 63, 1187-1189.	1.5	4
13	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. <i>Nature Reviews Cardiology</i> , 2017, 14, 577-590.	6.1	443
14	Mendelian randomisation in cardiovascular research: an introduction for clinicians. <i>Heart</i> , 2017, 103, 1400-1407.	1.2	126
15	Investigational therapies for hypercholesterolemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 603-617.	1.9	4
16	Can <scp>LDL</scp> cholesterol be too low? Possible risks of extremely low levels. <i>Journal of Internal Medicine</i> , 2017, 281, 534-553.	2.7	69
17	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
18	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , 2017, 49, 1758-1766.	9.4	470

#	ARTICLE	IF	CITATIONS
19	Proprotein-Convertase Subtilisin-Kexin Type 9 and Low-Density Lipoprotein Receptor Genotype Distribution and Statin Association in Filipino American Women. , 2017, 1, 108-115.	0.8	0
20	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Current Diabetes Reports, 2017, 17, 112.	1.7	22
21	PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Current Atherosclerosis Reports, 2017, 19, 49.	2.0	31
22	Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. Aids, 2017, 31, 2367-2376.	1.0	19
23	Methylglyoxal attenuates insulin signaling and downregulates the enzymes involved in cholesterol biosynthesis. Molecular BioSystems, 2017, 13, 2338-2349.	2.9	11
24	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 941-950.	5.5	452
25	PCSK9 inhibition and type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2017, 5, 926-927.	5.5	1
26	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM–INSULIN</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	2.2	105
28	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. European Journal of Preventive Cardiology, 2017, 24, 1870-1877.	0.8	55
29	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. American Journal of Cardiology, 2017, 120, 1521-1527.	0.7	36
30	Recent Developments in Mendelian Randomization Studies. Current Epidemiology Reports, 2017, 4, 330-345.	1.1	553
31	Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. Expert Review of Cardiovascular Therapy, 2017, 15, 923-932.	0.6	10
32	The impact of triglycerides on glucose tolerance: Lipotoxicity revisited. Diabetes and Metabolism, 2017, 43, 314-322.	1.4	36
33	Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?. Expert Review of Cardiovascular Therapy, 2017, 15, 491-494.	0.6	8
34	Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology, 2017, 18, 147.	0.8	12
35	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular Diabetology, 2017, 16, 70.	2.7	25
36	Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. International Journal of Epidemiology, 2017, 46, 2078-2089.	0.9	123
37	Treating Dyslipidemia in Type 2 Diabetes. Cardiology Clinics, 2018, 36, 233-239.	0.9	11

#	ARTICLE	IF	CITATIONS
38	Signalling pathways regulating galactosaminoglycan synthesis and structure in vascular smooth muscle: Implications for lipoprotein binding and atherosclerosis. , 2018, 187, 88-97.		26
39	Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes and Metabolism, 2018, 44, 508-513.	1.4	40
40	Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?. Trends in Endocrinology and Metabolism, 2018, 29, 420-434.	3.1	31
41	A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. Cell Reports, 2018, 23, 327-336.	2.9	76
42	Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. European Heart Journal, 2018, 39, 354-359.	1.0	43
43	The Genetic Link Between Diabetes and Atherosclerosis. Canadian Journal of Cardiology, 2018, 34, 565-574.	0.8	15
44	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. Pharmacological Research, 2018, 130, 1-11.	3.1	22
45	Alirocumab vs usual lipid-lowering care as addition to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY 4 randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1479-1489.	2.2	76
46	Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2018, 20, 1391-1398.	2.2	50
47	Mice Fed a High-Cholesterol Diet Supplemented with Quercetin Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas. Molecular Nutrition and Food Research, 2018, 62, e1700729.	1.5	29
48	PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. Postgraduate Medicine, 2018, 130, 287-298.	0.9	8
49	Hypolipidemic Drugs and Diabetes Mellitus—Mechanisms and Data From Genetic Trials. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 187-191.	1.0	5
50	Effects of evolving lipid-lowering drugs on carbohydrate metabolism. Diabetes Research and Clinical Practice, 2018, 137, 1-9.	1.1	2
51	Questioning the safety and benefits of evolocumab. Lancet Diabetes and Endocrinology,the, 2018, 6, 11.	5.5	3
52	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
53	Pharmacogenomics of blood lipid regulation. Pharmacogenomics, 2018, 19, 651-665.	0.6	3
54	Unexplained reciprocal regulation of diabetes and lipoproteins. Current Opinion in Lipidology, 2018, 29, 186-193.	1.2	17
55	Does addressing prediabetes help to improve population health?. Lancet Diabetes and Endocrinology,the, 2018, 6, 354-356.	5.5	7

#	ARTICLE	IF	CITATIONS
56	Electronic health records: the next wave of complex disease genetics. <i>Human Molecular Genetics</i> , 2018, 27, R14-R21.	1.4	38
57	An update on trials of novel lipid-lowering drugs. <i>Current Opinion in Cardiology</i> , 2018, 33, 416-422.	0.8	5
58	PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 270-282.	2.2	22
59	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <i>Journal of Clinical Lipidology</i> , 2018, 12, 130-136.	0.6	44
60	The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 409-418.	2.3	42
61	Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm. <i>JAMA Cardiology</i> , 2018, 3, 26.	3.0	75
62	Using Human "Experiments of Nature"™ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. <i>Drug Safety</i> , 2018, 41, 303-311.	1.4	22
63	Evaluation of the Pleiotropic Effects of Statins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 262-265.	1.1	32
64	Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. <i>Diabetic Medicine</i> , 2018, 35, 121-130.	1.2	31
65	Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?. <i>Current Opinion in Lipidology</i> , 2018, 29, 333-339.	1.2	22
67	Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 1076-1078.	1.0	7
68	Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1600-1605.	0.8	29
69	Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. <i>Circulation</i> , 2018, 138, 2499-2512.	1.6	69
70	Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. <i>Cardiovascular Diabetology</i> , 2018, 17, 155.	2.7	34
71	Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus. <i>Drugs in Context</i> , 2018, 7, 1-7.	1.0	14
72	Key aspects of PCSK9 inhibition beyond LDL lowering. <i>Current Opinion in Lipidology</i> , 2018, 29, 453-458.	1.2	10
73	A Mendelian randomization study of the effects of blood lipids on breast cancer risk. <i>Nature Communications</i> , 2018, 9, 3957.	5.8	121
74	Letter by Koh Regarding Article, "PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)" <i>Circulation</i> , 2018, 138, 1283-1284.	1.6	0

#	ARTICLE	IF	CITATIONS
75	Large-Scale Phenome-Wide Association Study of <i>PCSK9</i> Variants Demonstrates Protection Against Ischemic Stroke. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002162.	1.6	48
76	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , 2018, 15, 757-769.	6.1	239
77	C679X loss-of-function PCSK9 variant lowers fasting glucose levels in a black South African population: A longitudinal study. <i>Diabetes Research and Clinical Practice</i> , 2018, 144, 279-285.	1.1	8
78	Body mass index modulates the association between CDKAL1 rs10946398 variant and type 2 diabetes among Taiwanese women. <i>Scientific Reports</i> , 2018, 8, 13235.	1.6	14
79	Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. <i>PLoS Medicine</i> , 2018, 15, e1002642.	3.9	22
80	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2389-2398.	2.2	19
81	Further options for treating lipids in people with diabetes: targeting <i>LDL</i> cholesterol and beyond. <i>Diabetic Medicine</i> , 2018, 35, 1173-1180.	1.2	3
82	Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2018, 20, 56.	1.3	2
83	The MR-Base platform supports systematic causal inference across the human phenome. <i>ELife</i> , 2018, 7, .	2.8	3,639
84	Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 995-1010.	1.1	109
85	PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	54
86	Mendelian randomisation in type 2 diabetes and coronary artery disease. <i>Current Opinion in Genetics and Development</i> , 2018, 50, 111-120.	1.5	13
87	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. <i>Atherosclerosis</i> , 2018, 276, 124-130.	0.4	27
88	Common Methods for Performing Mendelian Randomization. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 51.	1.1	105
89	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 44.	1.0	3
90	PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 567-578.	0.6	11
91	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 72, 314-329.	1.2	162
92	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1680.	1.8	41

#	ARTICLE	IF	CITATIONS
93	Shared Genetic Contribution of Type 2 Diabetes and Cardiovascular Disease: Implications for Prognosis and Treatment. <i>Current Diabetes Reports</i> , 2018, 18, 59.	1.7	25
94	Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001992.	1.6	37
95	PCSK9. <i>Circulation Research</i> , 2018, 122, 1420-1438.	2.0	198
96	Genomic insights into the causes of type 2 diabetes. <i>Lancet, The</i> , 2018, 391, 2463-2474.	6.3	110
97	Inactivation of the E3 Ubiquitin Ligase IDOL Attenuates Diet-Induced Obesity and Metabolic Dysfunction in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1785-1795.	1.1	22
98	Lowering <sc>LDL</sc>â€™Cholesterol and <sc>CV</sc> Benefits: Is There a Limit to How Low <sc>LDL</sc>â€™ Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 290-296.	2.3	6
99	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 747-754.	0.5	2
100	PCSK9 in diabetes: sweet, bitter or sour?. <i>European Heart Journal</i> , 2019, 40, 369-371.	1.0	8
101	Food patterns in relation to weight change and incidence of type 2 diabetes, coronary events and stroke in the MalmÃ¶ Diet and Cancer cohort. <i>European Journal of Nutrition</i> , 2019, 58, 1801-1814.	1.8	26
102	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. <i>European Heart Journal</i> , 2019, 40, 357-368.	1.0	124
103	The Niemannâ€™Pick C1-like 1 rs2073547 polymorphism is associated with type 2 diabetes mellitus in a Chinese population. <i>Journal of International Medical Research</i> , 2019, 47, 4260-4271.	0.4	1
104	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2019, 7, 618-628.	5.5	207
105	Efficacy and safety of PCSK9 monoclonal antibodies. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1191-1201.	1.0	16
106	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5253-5262.	1.8	4
107	Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. <i>Cardiovascular Diabetology</i> , 2019, 18, 144.	2.7	33
108	The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process â€™ is there a link?. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2019, 16, 128-132.	0.1	2
109	Pancreatic PCSK9 and its involvement in diabetes. <i>Journal of Thoracic Disease</i> , 2019, 11, S2018-S2022.	0.6	3
110	Au-delÃ du risque cardiovasculaire : le rÃle des lipoprotÃines contenant lâ€™apoB athÃrogÃnes dans lâ€™Ãtiologie du diabÃte de type 2. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, 129-139.	0.1	3

#	ARTICLE	IF	CITATIONS
111	Efficacité et sécurité des inhibiteurs de PCSK9 dans le diabète. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, 147-155.	0.1	1
112	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
113	Lipid-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 386-404.	2.0	124
114	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 364-385.	2.0	45
115	Genetic Insights for Drug Development in NAFLD. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 506-516.	4.0	52
116	Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 39-51.	2.2	8
117	Diabetogenic Action of Statins: Mechanisms. <i>Current Atherosclerosis Reports</i> , 2019, 21, 23.	2.0	43
118	Cholesterol metabolism, pancreatic β^2 -cell function and diabetes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2149-2156.	1.8	76
119	Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. <i>Toxicology and Applied Pharmacology</i> , 2019, 370, 170-177.	1.3	18
120	C679X loss-of-function PCSK9 variant is associated with lower fasting glucose in black South African adolescents: Birth to Twenty Plus Cohort. <i>Journal of Clinical and Translational Endocrinology</i> , 2019, 16, 100186.	1.0	6
121	Cardiovascular events, diabetes and guidelines: the virtue of simplicity. <i>Cardiovascular Diabetology</i> , 2019, 18, 42.	2.7	19
122	Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. <i>Diabetologia</i> , 2019, 62, 948-958.	2.9	41
123	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 930-949.	0.8	64
124	A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. <i>Npj Genomic Medicine</i> , 2019, 4, 3.	1.7	26
125	Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes? <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2791-2797.	1.1	6
126	Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. <i>JHEP Reports</i> , 2019, 1, 418-429.	2.6	51
127	Doubling of Hemoglobin A1c on PCSK9 Inhibitor Therapy. <i>American Journal of Medicine</i> , 2019, 132, e17-e18.	0.6	4
128	Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase) Tj ETQq1 1 0,784314 rgBT /Overl	1.6	25

#	ARTICLE	IF	CITATIONS
129	Inhibiting PCSK9 " biology beyond LDL control. <i>Nature Reviews Endocrinology</i> , 2019, 15, 52-62.	4.3	96
130	PCSK9 inhibitors and diabetes: Translational biology to clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 451-453.	2.2	0
131	Management of Diabetes Mellitus. <i>Contemporary Cardiology</i> , 2019, , 113-177.	0.0	0
132	Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials. <i>Diabetes and Metabolism</i> , 2020, 46, 280-287.	1.4	1
133	Target discovery using biobanks and human genetics. <i>Drug Discovery Today</i> , 2020, 25, 438-445.	3.2	4
134	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
135	Lipid lowering and Alzheimer disease risk: A mendelian randomization study. <i>Annals of Neurology</i> , 2020, 87, 30-39.	2.8	64
136	Inclisiran"New hope in the management of lipid disorders?. <i>Journal of Clinical Lipidology</i> , 2020, 14, 16-27.	0.6	80
137	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. <i>International Journal of Cardiology</i> , 2020, 299, 289-295.	0.8	1
138	Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 343-353.	1.0	17
139	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. <i>Atherosclerosis</i> , 2020, 293, 49-56.	0.4	21
140	Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study. <i>Pharmacogenomics Journal</i> , 2020, 20, 462-470.	0.9	18
141	LDL Cholesterol and Dysglycemia: an Intriguing Physiological Relationship. <i>Diabetes</i> , 2020, 69, 2058-2060.	0.3	0
142	Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders. <i>Frontiers in Endocrinology</i> , 2020, 11, 556610.	1.5	4
144	Polymorphisms of the Gene Encoding Cytochrome b-245 Beta Chain of NADPH Oxidase: Relationship with Redox Homeostasis Markers and Risk of Type 2 Diabetes Mellitus. <i>Russian Journal of Genetics</i> , 2020, 56, 856-862.	0.2	5
145	Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. <i>Cardiovascular Research</i> , 2020, 116, e136-e139.	1.8	29
146	Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1477-1489.	1.4	2
147	White Adipose Tissue Surface Expression of LDLR and CD36 is Associated with Risk Factors for Type 2 Diabetes in Adults with Obesity. <i>Obesity</i> , 2020, 28, 2357-2367.	1.5	14

#	ARTICLE	IF	CITATIONS
148	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3613-3682.	1.8	63
149	PhenomeXcan: Mapping the genome to the phenome through the transcriptome. <i>Science Advances</i> , 2020, 6, .	4.7	83
150	<p>Safety and Tolerability of PCSK9 Inhibitors: Current Insights</p>. <i>Clinical Pharmacology: Advances and Applications</i> , 2020, Volume 12, 191-202.	0.8	20
151	PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. <i>Frontiers in Physiology</i> , 2020, 11, 595819.	1.3	49
152	Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 209.	2.7	12
153	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 409-417.	1.0	15
154	Phenotypic and Genetic Characterization of Lower LDL Cholesterol and Increased Type 2 Diabetes Risk in the UK Biobank. <i>Diabetes</i> , 2020, 69, 2194-2205.	0.3	52
155	New Pharmacological Approaches to Target PCSK9. <i>Current Atherosclerosis Reports</i> , 2020, 22, 24.	2.0	41
156	PCSK9 Inhibitors in Secondary Preventionâ€™An Opportunity for Personalized Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 410-420.	0.8	11
157	Low cholesterol syndrome and drug development. <i>Current Opinion in Cardiology</i> , 2020, 35, 423-427.	0.8	1
158	Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	68
159	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092456.	1.1	8
160	What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. <i>Cardiology and Therapy</i> , 2020, 9, 59-73.	1.1	16
161	A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America. <i>Advances in Therapy</i> , 2020, 37, 1754-1777.	1.3	0
162	Application of magnetic nanoparticles in nucleic acid detection. <i>Journal of Nanobiotechnology</i> , 2020, 18, 62.	4.2	157
163	A network analysis framework of genetic and nongenetic risks for type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 461-469.	2.6	4
164	Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. <i>British Journal of Pharmacology</i> , 2021, 178, 2168-2185.	2.7	7
165	Precision Medicine and Informatics. , 2021, , 941-966.		0

#	ARTICLE	IF	CITATIONS
166	Editorial comment: when Mendelian randomization goes astray. <i>Current Opinion in Lipidology</i> , 2021, 32, 79-80.	1.2	3
167	New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. <i>BMC Pharmacology & Toxicology</i> , 2021, 22, 11.	1.0	1
168	The Interface of Therapeutics and Genomics in Cardiovascular Medicine. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 663-676.	1.3	8
169	Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes. <i>Frontiers in Physiology</i> , 2021, 12, 593862.	1.3	16
170	Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface expression of LDLR and CD36 and NLRP3 inflammasome. <i>Physiological Reports</i> , 2021, 9, e14721.	0.7	15
171	Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. <i>Nature Reviews Cardiology</i> , 2021, 18, 435-453.	6.1	88
172	Low-Density Lipoprotein Cholesterol Is Associated With Insulin Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1576-1584.	1.8	10
173	Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia. <i>Endocrinology and Metabolism</i> , 2021, 36, 279-295.	1.3	16
174	Variants of PCSK9 Gene Are Associated with Subclinical Atherosclerosis and Cardiometabolic Parameters in Mexicans. <i>The GEA Project. Diagnostics</i> , 2021, 11, 774.	1.3	7
175	Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2021, 20, 89.	2.7	9
176	Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 664583.	1.1	1
177	Endogenous PCSK9 may influence circulating CD45neg/CD34bright and CD45neg/CD34bright/CD146neg cells in patients with type 2 diabetes mellitus. <i>Scientific Reports</i> , 2021, 11, 9659.	1.6	8
178	Cohort profile: follow-up of a Berlin Aging Study II (BASE-II) subsample as part of the GendAge study. <i>BMJ Open</i> , 2021, 11, e045576.	0.8	24
179	A phenome-wide association study of genetically mimicked statins. <i>BMC Medicine</i> , 2021, 19, 151.	2.3	16
180	Skutki hamowania funkcji PCSK9 w obrębie wybranych tkanek. <i>Postepy Higieny i Medycyny Doswiadczalnej</i> , 2021, 75, 385-397.	0.1	2
181	Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. <i>Atherosclerosis</i> , 2021, 326, 47-55.	0.4	18
182	The year 2020 in Atherosclerosis. <i>Atherosclerosis</i> , 2021, 326, 35-44.	0.4	1
183	Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives. <i>The Lancet Healthy Longevity</i> , 2021, 2, e317-e326.	2.0	41

#	ARTICLE	IF	CITATIONS
184	PCSK9 and Inflammation: Their Role in Autoimmune Diseases, with a Focus on Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Current Medicinal Chemistry</i> , 2022, 29, 970-979.	1.2	10
185	Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes. <i>BMC Research Notes</i> , 2021, 14, 309.	0.6	2
186	The emerging landscape of peptide-based inhibitors of PCSK9. <i>Atherosclerosis</i> , 2021, 330, 52-60.	0.4	23
187	Substantial PCSK9 inactivation in β^2 -cells does not modify glucose homeostasis or insulin secretion in mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158968.	1.2	24
188	Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-11.	1.0	5
189	PCSK9 and cancer: Rethinking the link. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111758.	2.5	41
191	Berlin Aging Study II (BASE-II). , 2019, , 1-8.		3
192	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. <i>Nature Genetics</i> , 2017, 49, 1450-1457.	9.4	218
193	The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 143-152.	0.5	1
200	Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease. <i>Circulation Research</i> , 2020, 126, 1526-1548.	2.0	58
201	Genetically Mediated Lipid Metabolism and Risk of Insulin Resistance: Insights from Mendelian Randomization Studies. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 132.	1.1	7
202	PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort. <i>PLoS ONE</i> , 2020, 15, e0239752.	1.1	9
203	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. <i>European Cardiology Review</i> , 2020, 15, 1-9.	0.7	38
204	LDL-C plays a causal role on T2DM: a Mendelian randomization analysis. <i>Aging</i> , 2020, 12, 2584-2594.	1.4	14
205	Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus. <i>Annals of Translational Medicine</i> , 2018, 6, 130-130.	0.7	8
206	A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1790-1817.	1.0	13
207	Effects of Evolocumab on Cardiovascular Events. <i>Current Cardiology Reviews</i> , 2017, 13, 319-324.	0.6	3
208	Associations for BCO2, PCSK9, and TR1B1 Polymorphism and Lifestyle Factors with Ischemic Stroke: A Nested Case-Control Study. <i>Yonsei Medical Journal</i> , 2019, 60, 659.	0.9	9

#	ARTICLE	IF	CITATIONS
209	PCSK9 and carbohydrate metabolism: A double-edged sword. <i>World Journal of Diabetes</i> , 2017, 8, 311.	1.3	16
210	LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue. <i>Journal of Biomedical Research</i> , 2020, 34, 251.	0.7	18
211	Association of Low-Density Lipoprotein With All-Cause and Cause-Specific Mortality Among Us Adults. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
212	Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study. <i>Frontiers in Nutrition</i> , 2021, 8, 755834.	1.6	6
213	Human Genomics and Drug Development. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a039230.	2.9	16
216	Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?. <i>Annals of Translational Medicine</i> , 2018, 6, 60-60.	0.7	0
218	PCSK9 inhibitors and diabetes mellitus. <i>Vnitřni Lekarstvi</i> , 2018, 64, 1186-1189.	0.1	4
219	Treating hypercholesterolaemia with evolocumab. <i>Intervencni A Akutni Kardiologie</i> , 2018, 17, 212-217.	0.0	0
220	Novel Therapies for Dyslipidemia. , 0, , .		0
223	The Role of Mitochondrial DNA (mtDNA) in the Development of Diabetic Retinopathy (DR): A Systematic Review. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2017, 6, 30-38.	0.4	3
224	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. <i>Metabolites</i> , 2021, 11, 807.	1.3	17
225	Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. <i>Diabetes Care</i> , 2022, 45, 232-240.	4.3	10
226	Effect of Loss-of-Function Genetic Variants in <i>PCSK9</i> on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function. <i>Diabetes Care</i> , 2022, 45, 251-254.	4.3	1
227	Recessive Genome-Wide Meta-analysis Illuminates Genetic Architecture of Type 2 Diabetes. <i>Diabetes</i> , 2022, 71, 554-565.	0.3	7
228	Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics". <i>Science Translational Medicine</i> , 2021, 13, eabf4530.	5.8	1
229	Berlin Aging Study II (BASE-II). , 2021, , 649-656.		0
230	An Adverse Lipoprotein Phenotype- Hypertriglyceridemic HyperapoB- and the Long-Term Risk of Type 2 Diabetes Mellitus. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
231	An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, , 1-9.	1.5	7

#	ARTICLE	IF	CITATIONS
232	Dissecting the IL6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. British Journal of Clinical Pharmacology, 2022, 88, 2875-2884.	1.1	29
233	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. Atherosclerosis, 2022, 343, 28-50.	0.4	12
234	Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes. Clinical Therapeutics, 2022, 44, 331-348.	1.1	4
235	Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study. Journal of Nutrition, 2022, 152, 1283-1290.	1.3	0
236	Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 643-658.	1.4	4
238	Investigating the effects of statins on ischemic heart disease allowing for effects on body mass index: a Mendelian randomization study. Scientific Reports, 2022, 12, 3478.	1.6	3
239	The biological relevance of PCSK9: when less is better. Biochemistry and Cell Biology, 2022, 100, 189-198.	0.9	4
240	Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study. EBioMedicine, 2022, 78, 103953.	2.7	23
241	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. European Journal of Preventive Cardiology, 2022, 29, 1334-1342.	0.8	16
242	Mendelian randomization in pharmacogenomics: The unforeseen potentials. Biomedicine and Pharmacotherapy, 2022, 150, 112952.	2.5	10
243	Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism. Frontiers in Cardiovascular Medicine, 2022, 9, 879355.	1.1	8
244	An adverse lipoprotein phenotype—hypertriglyceridaemic hyperapolipoprotein B—and the long-term risk of type 2 diabetes: a prospective, longitudinal, observational cohort study. The Lancet Healthy Longevity, 2022, 3, e339-e346.	2.0	5
245	Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management. EBioMedicine, 2022, 80, 104038.	2.7	7
246	Alteration in Rab11-mediated endocytic trafficking of LDL receptor contributes to angiotensin II-induced cholesterol accumulation and injury in podocytes. Cell Proliferation, 2022, 55, e13229.	2.4	4
248	Proprotein convertase PCSK9 affects expression of key surface proteins in human pancreatic beta cells via intracellular and extracellular regulatory circuits. Journal of Biological Chemistry, 2022, 298, 102096.	1.6	6
249	PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. Cardiovascular Diabetology, 2022, 21, .	2.7	27
250	Association of genetic polymorphisms of PCSK9 with type 2 diabetes in Uyгур Chinese population. BMC Cardiovascular Disorders, 2022, 22, .	0.7	1
251	Molecular and cellular biology of PCSK9: impact on glucose homeostasis. Journal of Drug Targeting, 2022, 30, 948-960.	2.1	8

#	ARTICLE	IF	CITATIONS
252	Chasing LDL cholesterol to the bottom – PCSK9 in perspective. , 2022, 1, 554-561.		13
254	Safety of Statins and Nonstatins for Treatment of Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, 51, 655-679.	1.2	7
255	PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era. Current Atherosclerosis Reports, 2022, 24, 779-790.	2.0	5
256	Pancreatic PCSK9 controls the organization of the Î²-cell secretory pathway via LDLR-cholesterol axis. Metabolism: Clinical and Experimental, 2022, 136, 155291.	1.5	10
257	Hepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia. Cell Reports, 2022, 40, 111259.	2.9	9
258	Colesevelam – a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia. Expert Opinion on Pharmacotherapy, 2022, 23, 1363-1370.	0.9	2
259	Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease. JAMA Cardiology, 2022, 7, 955.	3.0	21
260	Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study. International Journal of Molecular Sciences, 2022, 23, 10418.	1.8	10
261	Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 385-396.	1.8	8
262	Statistical methods for Mendelian randomization with two-sample summary-level data. Genetic Epidemiology, 2023, 47, 3-25.	0.6	29
263	Using human genetics to improve safety assessment of therapeutics. Nature Reviews Drug Discovery, 2023, 22, 145-162.	21.5	20
264	PCSK9 Inhibition and Risk of Diabetes: Should We Worry?. Current Atherosclerosis Reports, 2022, 24, 995-1004.	2.0	12
265	Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation. , 2022, 1, 41-47.		0
266	Association of PCSK9 Loss-of-Function Variants With Risk of Heart Failure. JAMA Cardiology, 0, , .	3.0	1
267	PCSK9 inhibition and cholesterol homeostasis in insulin producing Î²-cells. Lipids in Health and Disease, 2022, 21, .	1.2	6
268	Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes PCSK9–Dependent Adipose Insulin Resistance. Nutrients, 2022, 14, 5314.	1.7	3
269	Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization. Current Cardiology Reports, 2023, 25, 67-76.	1.3	1
270	Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study. Journal of Inflammation Research, 0, Volume 16, 269-282.	1.6	0

#	ARTICLE	IF	CITATIONS
271	Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 149, 105155.	2.9	9
272	Elevated remnant cholesterol increase 6-year type 2 diabetes mellitus onset risk. <i>Clinica Chimica Acta</i> , 2023, 541, 117253.	0.5	2
273	Statins and diabetes: What are the connections?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101749.	2.2	11
274	Harnessing the potential of machine learning and artificial intelligence for dementia research. <i>Brain Informatics</i> , 2023, 10, .	1.8	8
275	Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function. <i>Cardiovascular Research</i> , 2023, 119, 1537-1552.	1.8	2
276	Low cholesterol states: clinical implications and management. <i>Expert Review of Endocrinology and Metabolism</i> , 0, , .	1.2	1
278	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
281	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. <i>Contemporary Diabetes</i> , 2023, , 821-878.	0.0	0
283	Cardiovascular disease and its association with insulin resistance and cholesterol. , 2023, , 205-236.		0